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Management of Impotence After Treatment of Carcinoma 
of the Prostate 
Dinesh J. Telang, MD,* and Riad N. Farah, MD* 
Impotence commonly occurs as a resuh of treatment of carcinoma ofthe prostate. We review the 
etiology, evaluation, and treatment options availahle for these patients as weU as our experience with 
fifty prostate cancer patients who underwent placement of penile prostheses. Several excellent 
alternatives are availahle for patients with impotence resulting from treatment of carcinoma ofthe 
prostate. (Henry Ford Ho.sp MedJ 1992:40:111-3) 
Impotence from treatment of carcinoma of the prostate occurs with all known modalities of treatment, including radical 
prostatectomy, extemal beam radiation therapy, and hormonal 
therapy. 
The incidence of postoperative impotence was 91% to 100% 
(1) until Walsh et al (2) first described the nerve-sparing ana-
tomic approach to radical retropubic prostatectomy in 1983. 
Walsh et afs description of the anatomy of the dorsal vein com-
plex and the neurovascular bundles (which innervate the caver-
nosal bodies responsible for erection) revived interest in per-
forming radical surgery for localized cancer of the prostate. 
These techniques brought morbidity, in terms of impotence, in-
continence, and blood loss, to an acceptable level. Of 61 potent 
patients undergoing nerve-sparing prostatectomy by a single 
staff urologist at Henry Ford Hospital between January 1986 to 
June 1990,57% regained potency within one year of their opera-
tion (3). Not all patients, however, are candidates for nerve-spar-
ing prostatectomy because of the stage or the location ofthe tu-
mor within the prostate. Regaining erectile function is also 
highly dependent on other factors, most importantiy age (4). 
Extemal beam radiation therapy causes local fibrosis and 
sclerosis of tissues which may result in erectile dysfunction of 
vascular and/or neurologic origin. Impotence ranged from 40% 
to 60% in one reported series (5). 
Hormonal therapy, usually reserved for locally advanced or 
metastatic adenocarcinoma of the prostate, consists of exoge-
nously administered luteinizing hormone-releasing hormone 
analogues (leuprolide, goserelin acetate), estrogens (diethylstil-
bestrol), or surgical castration. While its mechanisms are not 
completely understood, circulating testosterone is responsible 
for libido and plays a role in maintaining erectile function. 
Evaluation 
The evaluation of impotence after treatment of prostate can-
cer is somewhat simplified since the etiology of the impotence is 
clear and, perhaps more importantly, method of treatment is 
guided by the patient and his partner's preference. A detailed 
history and physical and neurological examinations are neces-
sary. Other testing, such as noctumal penile tumescence testing 
and psychometric examinations, may be requested in some in-
stances. Intracavemosal injection of vasoactive substances such 
as papaverine or prostaglandin E can be used in evaluation as 
well as in treatment. 
Treatment 
Treatment options for impotence (from least to most inva-
sive) include oral pharmacologic therapy, hormonal therapy, 
vacuum suction and penile constriction devices, intracavemosal 
injection therapy, penile revascularization and venous ligation 
procedures, and an anay of available penile prostheses. Hormo-
nal therapy (testosterone injection) is contraindicated in patients 
with a history of prostate cancer because of the androgen-de-
pendent nature of the disease. Revascularization procedures are 
generally reserved for younger patients with isolated arterial in-
flow disease (from trauma, for example). Our discussion will be 
limited to those modalities of clinical use in the prostate cancer 
patients. 
Oral pharmacologic therapy 
Yohimbine HCL is an indolic alkaloid obtained from the 
yohimbine tree. Yohimbine blocks presynaptic alpha-2 adrener-
gic receptors; the net effect on the peripheral autonomic nervous 
system is to decrease sympathetic outflow and increase para-
sympathetic activity, tt may act to elevate mood and anxiety and 
has been used in the past as an aphrodisiac. Since erection is 
cholinergically mediated through the parasympathetic nervous 
system, yohimbine may potentiate penile inflow, decrease out-
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flow, or both (6). A recent published report noted no improve-
ment in performance when comparing yohimbine to placebo 
(7). 
Vacuum suction and penile constriction devices 
Vacuum suction and penile constriction devices involve 
placement of a cylindrical apparatus over the penis, which 
pumps out air and creates vacuum to engorge the penis; a con-
stricting band is then placed over the base of the phallus to main-
tain the erection. Advantages include low cost, low morbidity, 
and high satisfaction rates in patients with excellent manual 
dexterity who are highly motivated and have a supportive part-
ner (8). There have been no reports of serious complications, al-
though some patients complain of numbness while the con-
stricting band is in ptace. These devices have been utilized suc-
cessfully in some patients who have had penile prostheses ex-
planted and can be used in combination with intracavemosal in-
jection therapy (9). 
Intracavemosal injection therapy 
Use of intracavemosal injection of vasoactive agents is a rela-
tively recent development in the treatment of impotence. Early 
reports used papaverine with or without phentotamine; more re-
centiy prostaglandin E, alone or in various combinations with 
papaverine and phentotamine, has found favor. Advantages of 
intracavemosal injection include a physiologic erection that can 
be produced "on demand," the temporal nature of the treatment, 
and ease of administration. Insulin-dependent diabetic patients 
seem to be especially well suited to this type of therapy. Risk of 
infection is exceedingly low when used with proper sterilization 
techniques. 
As with vacuum constriction devices, injection therapy re-
quires a high level of manual dexterity as welt as a highly moti-
vated patient, tt does not preclude use of other treatment options 
should it not be an acceptable solution for a couple's sexual dys-
function. Disadvantages include pain with injection and the 
need to stock necessary syringes, needles, and medication. 
Complications include corporeal fibrosis (more common with 
papaverine) and priapism. One-year dropout rates from pharma-
cologic erection programs have been as high as 40% to 50% 
(10). 
Penile prostheses 
Modem silicone penile prostheses were introduced in the mid 
1960s. Several options are available. Semirigid prostheses are 
solid siticone with a centrat silver or stainless-steel wire to give 
rigidity. Mechanical failures are uncommon, and patient satis-
faction is high. The prosthesis is simply bent into position as de-
sired, requiring minimal manual dexterity. While these prosthe-
ses are simple to use, some patients complain of difficulty con-
cealing these devices when not in use. 
The first inflatable penile prosthesis was developed in 1973; 
plagued with problems early on, subsequent design improve-
ments have made the inflatable models reliable with 97% func-
tioning at three years in one study (11). The inflatable models 
closely mimic the appearance of a normal physiologic erection, 
are self-contained, and require no extemal paraphemalia. Pa-
tient satisfaction ranges from 83% to near 90%, with partner sat-
isfaction somewhat lower (12-14). Complications range from 
the need for simple revisions for mechanical failure to infection 
and erosion to gangrene of the penis. These complications are 
more likely to occur in poorly controlled diabetics; patients with 
neurogenic bladders on clean intermittent catheterization; pa-
tients with urinary diversions, cystostomy tubes, or colostomy; 
and paraplegics (15). 
We have extensive experience with penile prostheses at 
Henry Ford Hospital, with over 870 devices placed by a single 
staff urologist. We recently reviewed the medical records of 50 
patients with a history of carcinoma of the prostate who under-
went placement of a penile prosthesis. Patients ranged in age 
from 50 to 78 years (mean 65 years). Thirty-five patients elected 
inflatable prostheses; the remainder chose semirigid implants. 
Overall mean follow-up is 4.3 years (7.4 years for semirigid 
prostheses and 3.0 years for inflatable devices). The shorter fol-
low-up for inflatable prostheses is attributed to improvements in 
design in these prostheses in recent years. 
Five men underwent removal or revision of the prosthesis. 
One patient had his semirigid prosthesis removed because of 
problems with concealment; he refused revision to an inflatable 
model. Two patients had simple revisions (one from a semirigid 
to an inflatable prosthesis for erosion and the other for a pump 
malfunction); both of these patients cunently have functioning 
implants. The other two men had two or more unsuccessful revi-
sions or replacements of their inflatable prosthesis ultimately re-
sulting in removal of the device because of erosion or infection. 
These two patients have not been interested in further evaluation 
or treatment. 
The long-term complication rate in our series is 8%, half of 
which have been managed successfully. Risk factors for compli-
cations included diabetes in one patient and history of urinary 
tract infection in two patients. Thirteen of 15 patients with 
semirigid implants have had an uncomplicated postoperative 
course; 32 of 35 patients with inflatable implants have had no 
mechanical or technical problems with the device. The 90% 
complication-free rate and the 94% functional prosthesis rate 
are excellent in a cancer patient population. These rates are com-
parable to a previously reported series (10). Patient and partner 
satisfaction with penile prostheses at our institution is cunently 
being studied. In a series from the Mayo Clinic (12), patients 
who required more than one procedure for implantation of the 
prosthesis or who experienced pain or were dissatisfied with the 
cosmetic appearance of the device were least likely to be satis-
fied with the prosthesis. 
Cost 
The relative cost of intracavemosal injection versus semi-
rigid and inflatable penile prostheses has been studied. Buch et 
al (16) compared the calculated projected cost of intracaver-
nosal injection over a five-year period ($3,450) to the cost of a 
semirigid ($3,150) or inflatable penile prosthesis ($9,000) and 
concluded that prostheses were more cost-effective than intra-
cavemosal injection for young patients. However, this study did 
not calculate the cost of complications, revisions, or life expec-
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tancy of the patient or the prosthetic device. Vacuum suction 
and penile constriction devices cost approximately $300, Pros-
taglandin El ranges from $3 to $10 per injection depending on 
the dose required to obtain a satisfactory erection. Interestingly, 
insurance companies are highly variable with respect to cover-
age for evaluation and treatment of organic impotence 
Conclusion 
Impotence secondary to carcinoma of the prostate is becom-
ing increasingly more common as new methods of early detec-
tion have been developed (specifically prostate-specific antigen 
and transrectal sonography) and are now widely available. Sev-
eral excellent treatment altematives are available to prostate 
cancer patients with sexual dysfunction. With careful evaluation 
an acceptable and effective method of treatment is available to 
almost all of these patients. 
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